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25 GRAM VERSUS 50 GRAM OF 25%
ALBUMIN IN PREVENTING RENAL
IMPAIRMENT AFTER LARGE VOLUME
PARACENTESIS IN CIRRHOSIS

PREDICTORS OF HEALTH-RELATED
QUALITY OF LIFE IN PATIENTS WITH
LIVER CIRRHOSIS AT TERTIARY CARE
HOSPITAL, KARACHI

AB Khalid, K Mumtaz, A Ghufran, Hasnain Alishah,
S Hamid, W Jafri
Section of Gastroenterology, Department of Medicine,
Aga Khan University Hospital, Karachi, Pakistan

Om Parkash, R Iqbal, I Azam, W Jafri
Section of Gastroenterology, Department of Medicine,
Aga Khan University Hospital, Karachi, Pakistan

Background: Large volume paracentesis (LVP) in patients with cirrhosis may lead to significant hemodynamic
changes termed paracentesis-induced circulatory dysfunction (PICD). PICD is marked by increased renin, impaired
renal function (IRF), and decreased serum sodium. Intravenous albumin is effectively used to prevent PICD and
IRF. The exact dose of i.v. albumin, however, is not yet
established.
Aim: To compare 25 g and 50 g of 25% i.v. albumin to prevent IRF associated with PICD in patients with cirrhosis
undergoing LVP.
Method: Case records of patients with cirrhosis who underwent LVP from January 2008 to July 2010 were reviewed.
Patients with spontaneous bacterial peritonitis, creatinine
>1.5 mg/dL, hepatoma, coexisting malignancy, or paracentesis of <5 L were excluded. Demographics, etiology, and
laboratory parameters along with the amount of LVP and
the dose of albumin received were noted. Moreover, serum
creatinine and serum sodium at baseline and 1 week post
paracentesis were recorded.
Result: Two-hundred and fourteen patients with cirrhosis underwent LVP during the study period. Among them,
141 met the inclusion criteria and were included for analysis.
We found that 110 patients received 25 g of i.v. albumin
while 31 received 50 g of IV albumin after LVP. Mean age
in both these groups were 54 ± 11 and 53 ± 10 years, respectively. Hepatitis C was the predominant etiology which
was found in 70% and 55% in 25 g and 50 g albumin group,
respectively. More than 70% patients in both groups belonged to Child Turcot Pugh Class C. Mean ascitic fluid
removed was 6.7 L in 25 g albumin group while 8.5 L in
50 g albumin group. Serum creatinine at baseline and
1 week post-LVP was 1.04 ± 0.02 and 1.07 ± 0.03 in the 25 g
albumin group while 1.12 ± 0.04 and 1.41 ± 0.17 in 50 g
albumin, respectively (P = 0.35). Similarly, serum sodium at
baseline and 1 week post-LVP was 130.44 ± 3.5 and 129.62 ±
4.1 in the low-dose albumin group, while 129.62 ± 5.6 and
128.7 ± 6.0 in 50 g albumin (P = 0.14).
Conclusion: We conclude that 25 g of 25% i.v. albumin
may be as effective as 50 g in preventing renal impairment
after LVP in cirrhosis. The results of this study need further
validation in a large prospective cohort.

Introduction: Chronic liver disease/cirrhosis (CLD) in
individuals produces a variety of symptoms which in turn
lead to a negative impact on health-related quality of life
(HRQOL). However, no such work has been carried out in
Pakistan. The general aim of this study was to evaluate the
magnitude of poor HRQOL and to assess factors related
with HRQOL in patients with CLD.
Method: A cross-sectional study was conducted at the
Gastroenterology Clinics of Aga Khan University Hospital.
All adult patients diagnosed to have cirrhosis were invited to participate. In this study, Chronic Liver Disease
Questionnaire (CLDQ) was used to assess HRQOL of these
patients. Patients were categorized into 2 groups based
on CLDQ score; <5 as poor and ≥5 as good score for determination of the frequency of poor HRQOL. CLDQ score
was used as an outcome measure to determine the factors
related with HRQOL.
Result: Two-hundred and seventy-three participants were
recruited; 155 (57%) were males. Mean age of participants
was 49 years (SD ± 11 years). In this study, the most common cause for cirrhosis was viral infection 247 (91.5%).
Mean Child Turcot Pugh (CTP) score was 8 ± 1.85 and the
mean model for end stage liver disease (MELD) score was
12.6 ± 6.8. Two-hundred and nine patients (76.6%) had CTP
B or C class. Poor HRQOL was seen in 187 (69%) of the
participants. Mean CLDQ score was 4.36 (SD ± 1.1). Among
all of the domains, fatigue domain had significantly lower
CLDQ score. On multivariable analysis, hemoglobin (β =
0.09 [SE = 0.04]), albumin (β = 0.32 [SE = 0.09]), diastolic
blood pressure (DBP) (β = 0.01 [0.005]), and prior history
of decompensation (β = 0.98 [SE = 0.39] were the significant factors associated with HRQOL in patients with liver
cirrhosis.
Conclusion: Frequency of poor HRQOL determined
by CLDQ score is high in patients with liver cirrhosis.
Hemoglobin, serum albumen, diastolic blood pressure
and prior history of decompensation are associated with
HRQOL.

Journal of Clinical and Experimental Hepatology | September 2011 | Vol. 1 | No. 2 | 133–154

153

ILS – 2011

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY

